Showing results (41-50 of 123) with videos related to
Sort By:
Pageof 13
Oncology and Therapy|July 24, 2020
Real-World Impact of Physician and Patient Discordance on Health-Related Quality of Life in US Patients with Acute Myeloid LeukemiaL Elise Horvath Walsh, Alex Rider, James Piercy, et al.Journal of Clinical Microbiology|February 23, 2007
Graphium basitruncatum fungemia in a patient with acute leukemiaDeepali Kumar, Lynne Sigler, Connie Fe C Gibas, et al.American Journal of Hematology|November 5, 2011
Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemiaBruno C Medeiros, Holbrook E Kohrt, Jason Gotlib, et al.Haematologica|October 14, 2011
Treatment advances have not improved the early death rate in acute promyelocytic leukemiaJames Scott McClellan, Holbrook E Kohrt, Steven Coutre, et al.Clinical Lymphoma, Myeloma & Leukemia|March 25, 2018
A Phase I/II Trial of the Combination of Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid LeukemiaBruno C Medeiros, Tiffany N Tanaka, Larisa Balaian, et al.Journal of Oncology Practice|August 15, 2013
Qualitative analysis of practicing oncologists' attitudes and experiences regarding collection of patient-reported outcomesReshma Jagsi, Anne Chiang, Blase N Polite, et al.Leukemia & Lymphoma|May 18, 2022
Factors associated with risk and prognosis of intensive care unit admission in patients with acute leukemia: a Danish nationwide cohort studyCecilie Velsoe Maeng, Christian Fynbo Christiansen, Kathleen Dori Liu, et al.Advances in Therapy|June 22, 2019
Economic and Clinical Burden of Relapsed and/or Refractory Active Treatment Episodes in Patients with Acute Myeloid Leukemia (AML) in the USA: A Retrospective Analysis of a Commercial Payer DatabaseBhavik J Pandya, Chi-Chang Chen, Bruno C Medeiros, et al.Blood Advances|March 10, 2020
Single-cell mutational profiling enhances the clinical evaluation of AML MRDAsiri Ediriwickrema, Alexey Aleshin, Johannes G Reiter, et al.British Journal of Haematology|April 5, 2016
A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myelomaTamara J Dunn, Shira Dinner, Elizabeth Price, et al.Pageof 13